AUTHORS
Xiaoyu Zhang, MD, Mingyue Xu2, Donglin Yang3, Sisi Feng4, Yarong Liu5, Aimin Pang6, Yi He, MD7, Pin Wang8, Erlie Jiang, MD9
AFFILIATIONS
1 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 Grit Biotherapeutics, Shanghai, China
5 Grit Biotherapeutics, Shanghai, China
6 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 Grit Biotherapeutics, Shanghai, China
9 State Key Laboratory of Experimental Hematology; Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Chronic graft-versus-host disease (cGVHD) remains a common complication of allogeneic hematopoietic cell transplantation (HSCT) and can have a devastating impact on overall health and quality of life (QoL). Although currently available therapies can produce high overall response rates (ORR), failure-free survival (FFS) remains suboptimal.
GT729 is an allogeneic invariant natural killer (iNKT) cell therapy generated through in vitro differentiation of cord blood–derived CD34+ hematopoietic stem cells (HSCs) genetically engineered with iNKT TCR. In pre-clinical studies, GT729 demonstrated potent anti-GVHD activity by eliminating antigen-presenting myeloid cells in vitro and in xenograft models, while preserving the antitumor activity of allogeneic T cells in lymphoma and leukemia models. A GMP-compliant manufacturing platform was established to support a phase I clinical trial evaluating the safety and feasibility of GT729 in patients with steroid-refractory or steroid-dependent cGVHD (NCT07253259). The study uses a standard 3+3 dose-escalation design with cohorts receiving 0.1, 0.5, and 1.0 x10^9 iNKTs/kg. To our knowledge, this is the first clinical investigation of a genetically engineered human iNKT product to treat cGVHD.
As of the data cutoff, four patients had been enrolled. Median age was 39 years (range, 32–46 years); one patient was female and three were male. All patients received peripheral blood stem cell grafts from matched sibling donors after myeloablative conditioning for acute lymphoblastic leukemia (n=1), myelodysplastic syndrome (n=2), or acute myeloid leukemia (n=1), and all received calcineurin inhibitor–based prophylaxis. Median time to cGVHD onset was 10 months (range, 8–12), and patients had received a median of 3.5 prior lines of therapy (range, 3–5), including belumosudil (n=3) and ruxolitinib (n=3). Organ involvement included scleroderma (n=2), joint/fascia (n=2), oral mucosa (n=1), ocular (n=1), and liver (n=1).
GT729 were successfully manufactured, cryopreserved, and infused without prior lymphodepleting chemotherapy. No serious adverse events (AEs), immune effector cell-associated neurotoxicity syndrome (ICANS), or infections were observed during the DLT evaluation period. One grade 1 cytokine release syndrome (CRS) event was reported. Other AEs during this period were hyperglycemia (n=1), insomnia (n=1), edema (n=1), and fever (n=1). All four patients achieved a partial response (PR) at day 28 according to NIH consensus criteria. Two patients maintained a sustained PR exceeding 3 months; one achieved a complete response (CR) at 6 months and successfully tapered concomitant immunosuppressive therapy.
Translational analysis showed that GT729 cells reached peak peripheral-blood levels within the first month after infusion and remained detectable after multiple infusions across dose levels, without evidence of dose-dependent kinetics. Inflammatory cytokine levels decreased after infusion. One patient showed a sustained reduction in ST2 after the first infusion and a decrease in REG3A; decreases in granzyme B, MIG, IL-2RA, IL-1β, and IL-8 were observed in other patients.
In summary, early findings indicate that GT729 cell therapy is feasible and has an acceptable preliminary safety profile, with encouraging clinical activity in heavily pretreated cGVHD. Further enrollment and longer follow-up are needed to characterize durability, dose-response relationships, and immunologic effects.
DISCLOSURES
Xiaoyu Zhang, MD: No relevant conflicts of interest to declare.